Oral antivirals for COVID-19 among patients with cancer
Supportive Care in Cancer · 2024
DOI: 10.1007/s00520-024-08714-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Dorra Guermazi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Brown University, 69 Brown St. Providence, Providence, RI, 02912, USA. dorra_guermazi@brown.edu. Hauptthemen laut MEDLINE: Neoplasms, Antiviral Agents, Ritonavir, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE: Immunocompromised individuals, such as those diagnosed with cancer, are at a significantly higher risk for severe illness and mortality when infected with SARS-CoV-2 (COVID-19) than the general population. Two oral antiviral treatments are approved for COVID-19: Paxlovid® (nirmatrelvir/ritonavir) and Lagevrio® (molnupiravir). There is a paucity of data regarding the benefit from these antivirals among immunocompromised patients with cancer, and recent studies have questioned their efficacy among vaccinated patients, even those with risk factors for severe COVID-19. METHODS: We evaluated the efficacy and safety of nirmatrelvir/ritonavir and molnupiravir in preventing severe illness and death using our database of 457 patients with cancer and COVID-19 from Brown University-affiliated hospitals. RESULTS: Sixty-seven patients received nirmatrelvir/ritonavir or molnupiravir and were compared to 45 concurrent controls who received no antiviral treatment despite being eligible to receive it. Administration of nirmatrelvir/ritonavir or molnupiravir was associated with improved survival and lower 90-day all-cause and COVID-19-attributed mortality (p < 0.05) and with lower peak O2 requirements (ordinal odds ratio [OR] 1.52, 95% confidence interval [CI] 0.92-2.56). CONCLUSION: Acknowledging the small size of our sample as a limitation, we concluded that early antiviral treatment might be beneficial to immunocompromised individuals, particularly those with cancer, when infected with SARS-CoV-2. Larger-scale, well-stratified studies are needed in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brown University, 69 Brown St. Providence, Providence, RI, 02912, USA. dorra_guermazi@brown.edu.
- Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Gerry House 111, Providence, RI, 02903, USA. dorra_guermazi@brown.edu.
- Division of Infectious Diseases, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Gerry House 111, Providence, RI, 02903, USA.
- Center for Clinical Cancer Informatics and Data Science, Legorreta Cancer Center, Brown University, Providence, RI, 02912, USA.
- Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, 02906, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Guermazi, D., Arvanitis, P., Vieira, K., Warner, J. L., & Farmakiotis, D. (2024). Oral antivirals for COVID-19 among patients with cancer. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08714-w
Vancouver
Guermazi D, Arvanitis P, Vieira K, Warner JL, Farmakiotis D. Oral antivirals for COVID-19 among patients with cancer. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08714-w
BibTeX
@article{Guermazi2024,
author = {Guermazi, Dorra and Arvanitis, Panos and Vieira, Kendra and Warner, Jeremy L and Farmakiotis, Dimitrios},
title = {Oral antivirals for COVID-19 among patients with cancer},
journal = {Supportive Care in Cancer},
year = {2024},
doi = {10.1007/s00520-024-08714-w}
}
EUVIMED